NOTICE OF INTENT TO SOLE SOURCE - Psomagen, Inc. GEM-X Cell QC, sequencing and data analysis

Agency: HEALTH AND HUMAN SERVICES, DEPARTMENT OF
State: Maryland
Type of Government: Federal
FSC Category:
  • A - Research and development
NAICS Category:
  • 541990 - All Other Professional, Scientific, and Technical Services
Set Aside: No Set aside used
Posted Date: Sep 22, 2026
Due Date: Sep 21, 2026
Solicitation No: PCA-NCI-09798
Original Source: Please Login to View Page
Contact information: Please Login to View Page
Bid Documents: Please Login to View Page

Description

Follow
NOTICE OF INTENT TO SOLE SOURCE - Psomagen, Inc. GEM-X Cell QC, sequencing and data analysis
Active
Contract Opportunity
Notice ID
PCA-NCI-09798
Related Notice
Department/Ind. Agency
HEALTH AND HUMAN SERVICES, DEPARTMENT OF
Sub-tier
NATIONAL INSTITUTES OF HEALTH
Office
NIH NCI
General Information View Changes
  • Contract Opportunity Type: Special Notice (Updated)
  • Updated Published Date: Sep 22, 2026 10:28 am EDT
  • Original Published Date: Sep 15, 2026 12:50 pm EDT
  • Updated Response Date: Sep 21, 2026 12:00 pm EDT
  • Original Response Date: Sep 21, 2026 12:00 pm EDT
  • Inactive Policy: 15 days after response date
  • Updated Inactive Date: Oct 06, 2026
  • Original Inactive Date: Oct 06, 2026
  • Initiative:
    • None
Classification
  • Original Set Aside: No Set aside used
  • Product Service Code: AJ11 - GENERAL SCIENCE AND TECHNOLOGY R&D SERVICES; GENERAL SCIENCE AND TECHNOLOGY; BASIC RESEARCH
  • NAICS Code:
    • 541990 - All Other Professional, Scientific, and Technical Services
  • Place of Performance:
    Rockville , MD 20850
    USA
Description

Title: Psomagen, Inc. GEM-X Cell testing (ongoing studies)



This is a Notice of Intent to Sole Source (NOI), not a request for proposal. The National Cancer Institute intends to negotiate on an other-than-full-and-open competition basis with Psomagen, Inc., 1330 Piccard Dr., Suite 103, Rockville, MD 20850-4372 for quality control of submitted single cell samples, generation of sequencing libraries with 10X Chromium GEM-X Single Cell 5p RNA, and expression analysis data of (frozen) clinical xenograft biosamples. The testing is being obtained from Psomagen, Inc. to remain consistent with prior data of ongoing research studies. A critical factor in filling the requirement is the limited viability (no more than 2 hours transport time) of the irreplaceable study biosamples.



While this pre-solicitation does not constitute a solicitation, interested vendors may identify their interest and capability to satisfy this requirement. The Government understands that Psomagen, Inc. is the owner and developer of the required proprietary testing services currently used by NCI in its ongoing research studies. However, vendors who believe that they can provide the capability required to fully meet the Government's requirement may submit a capabilities statement, including past performance, in writing to the identified point of contact prior to the closing date and time of this notice. Interested parties should clearly address the challenge of integrating with existing Psomagen quality control, sequencing libraries and expression analysis data. Such documentation shall be evaluated solely for the purpose of determining whether or not to conduct this procurement on a competitive basis. A determination not to compete this requirement, based upon responses to this notice, is solely within the discretion of the Government. Interested parties may identify their interest and capability to respond to the requirement by referencing “PCA-NCI-09798.”



The statutory authority for this sole source requirement is 41 U.S.C. 3204(b)(2) as implemented by FAR Overhaul 12.102(a) only one source is available. THIS IS NOT A REQUEST FOR PROPOSAL.



All responsible sources that could provide comparable products may submit a capability statement via email to Christine Biser at:



ChristineBi@mail.nih.gov by 12:00 pm EASTERN Daylight Time, Wednesday, September 24, 2026.



Late submissions shall be treated in accordance with the solicitation provision at FAR 52.212-1(f). All responses received by the closing date of this synopsis will be considered by the Government. A determination not to compete this requirement, based upon responses to this notice, is solely within the discretion of the Government.



Any questions or concerns regarding this solicitation should be forwarded in writing via e-mail to Christine Biser at ChristineBi@mail.nih.gov.


Attachments/Links
Contact Information
Contracting Office Address
  • OFFICE OF ACQUISITIONS 31Center Dr. 11A35P
  • Bethesda , MD 20892
  • USA
Primary Point of Contact
Secondary Point of Contact


History
Get Government Bids Like This by Email Receive daily bid alerts that match your keywords, business categories, and target regions.

See Also

Follow Prototype development for Battlefield Wound Infection Prevention and Treatment (BWI P&T) Barrier

DEPT OF DEFENSE

Due by 10/23/2026

Follow Prototype development for Battlefield Wound Infection Prevention and Treatment (BWI P&T) Barrier

DEPT OF DEFENSE

Due by 10/23/2026

Follow Broad Agency Announcement DEVCOM C5ISR RTI Active Contract Opportunity Notice ID W56KGU23RRTID

DEPT OF DEFENSE

Due by 10/31/2027

Follow Generally Unconstrained Intelligence Drug Engineering (GUIDE) collaboration between U.S. interagency, academic and

DEPT OF DEFENSE

Due by 10/18/2028

* Disclaimer: This website provides information about bids, requests for proposals (RFPs), or requests for qualifications (RFQs) for convenience only and does not serve as an official public notice. Individuals who wish to respond to or inquire about bids, RFPs, or RFQs should contact the relevant government department directly.